Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




US FDA Demands Proof of Antibacterial Soap Claims

By HospiMedica International staff writers
Posted on 02 Jan 2014
Manufacturers of nonprescription antibacterial hand soaps and body washes will soon be required to show their products are more effective than plain soap in stopping the spread of infections. More...


The demand made by the US Food and Drug Administration (FDA; Silver Spring, MD, USA) does not apply to hand sanitizers and wipes, which are alcohol-based and are not used with water, or to antibacterial products used in the healthcare setting. Failing to meet these standards would mean that the antiseptic ingredients used in the products would have to be removed from over-the-counter (OTC) products, or that antibacterial claims are removed from product labeling. The FDA has been reviewing antibacterial active ingredients for the past several years, and hopes to finalize the rule by late 2016.

Over 2,200 antibacterial hand soaps and body washes are currently available for consumers in the United States alone, but there is no scientific evidence showing these products are any more effective at preventing illness than washing hands with plain soap and water. In fact, some data suggest that long-term exposure to certain active ingredients used in antibacterial products, such as triclosan and triclocarban, engender health risks such as bacterial resistance or hormonal imbalances (for example with estrogen, testosterone, and thyroid hormones).

“In order for antibacterial soaps and body washes to be considered generally recognized as effective, manufacturers would be required to conduct clinical trials demonstrating that their products are more effective than plain soap and water in preventing illness and the spread of certain infections when they're used by consumers,” said Sandra Kweder, MD, deputy director of the Office of New Drugs at the FDA's Center for Drug Evaluation and Research (CDER).

“Antibacterial soaps and body washes are used widely and frequently by consumers in everyday home, work, school, and public settings, where the risk of infection is relatively low,” said Janet Woodcock, MD, director of the CDER. “Due to consumers’ extensive exposure to the ingredients in antibacterial soaps, we believe there should be a clearly demonstrated benefit from using antibacterial soap to balance any potential risk.”

The proposed rule does not require the antibacterial soap products to be removed from the market at this time. When the proposed rule is finalized, either companies will have provided data to support an antibacterial claim, or if not, they will have to reformulate or re-label these products in order to continue marketing.

Related Links:

US Food and Drug Administration



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.